reboxetiini

Reboxetiini is a medication classified as a selective norepinephrine reuptake inhibitor (SNRI). It was developed for the treatment of major depressive disorder and, in some regions, attention deficit hyperactivity disorder (ADHD). The primary mechanism of action for reboxetiine involves increasing the levels of norepinephrine in the brain by blocking its reabsorption. Norepinephrine is a neurotransmitter believed to play a role in mood regulation, attention, and arousal.

The efficacy and tolerability of reboxetiine have been subjects of considerable research and debate. While some studies suggested it could be effective in treating depression, particularly in patients who did not respond to other antidepressants, other trials yielded less conclusive results. Its effectiveness for ADHD has also been investigated, with mixed findings. Common side effects associated with reboxetiine can include dry mouth, constipation, insomnia, nausea, and sweating. Less common side effects may involve increased heart rate, difficulty urinating, and sexual dysfunction.

Reboxetiine is not approved for use in the United States. It has received marketing authorization in several European countries. The decision to prescribe reboxetiine, like any medication, involves a careful assessment of potential benefits against risks, considering individual patient characteristics and medical history. Its use is generally monitored by healthcare professionals due to potential side effects and interactions with other medications.